Where is industrial spider silk? (Part 2)

Last updated: 2 November 2026 · 30 min read

Part 2 of 2 · Previous: Where is industrial spider silk? (Part 1)

Part Two: The Economics, The Survivors, and the Final Reckoning

The Money That Couldn’t Wait: Venture Capital, Economics, and the Cost of Almost

In 2009, the company that became Bolt Threads was incorporated (as Refactored Materials) and set up in Emeryville, California, with a vision to change how the world makes materials. By its chief executive’s account, it went on to raise about $334 million as a private company. In August 2024 it went public by merging with a Special Purpose Acquisition Company, listing on Nasdaq under the ticker BSLK. The shares, worth roughly $230 million on the first day of trading, collapsed within months: by early 2025 the market capitalization had fallen to around $10 million, the company carried about $13 million of secured debt owed to Ginkgo Bioworks, and it had received the first of several Nasdaq deficiency notices. In January 2026 Nasdaq suspended the stock, which moved to the over-the-counter market, and in March 2026 Bolt filed to stop reporting to the SEC.

Spiber, Bolt’s Japanese counterpart and the most heavily funded company in the space, raised more than ¥100 billion (roughly $650–700 million) in equity and debt after its 2007 founding as a Keio University spin-off. The revenue it disclosed was tiny by comparison: ¥414 million in 2024 and ¥177 million in 2025, against net losses of about ¥30 billion and ¥44 billion. In 2026, unable to repay a ¥35 billion loan that fell due at the end of 2025, it went through an out-of-court restructuring that moved its business into a new company. AMSilk, the German pioneer that has perhaps made more commercial headway than either of those two, raised €54 million across its Series C financing rounds, and in 2019 sold its cosmetics-ingredients business to Swiss flavor-and-fragrance group Givaudan to refocus on high-performance materials such as its Biosteel fiber. In 2023, it contracted with chemicals major Evonik Industries to manufacture proteins at industrial scale in Slovakia, a sign of progress, and of a company that chose to rent an established fermenter’s capacity rather than build its own plants. In September 2025, AMSilk announced a further €52 million (about $60 million) in equity and convertible bonds to scale up industrial production.

Companies that set out to commercialize recombinant spider silk have absorbed hundreds of millions of dollars over three decades, and by some counts more than a billion if Spiber’s loans and broader biomaterials spending are included. Much of it was later redirected to other protein materials. The return on that capital, measured in revenue, has been almost negligible. The likeliest cause is a structural mismatch between what the technology needed and what the financial system was willing to provide; neither fraud nor incompetence is needed to explain it.

How Hype Built Valuations on Air

From the outside, in the 1990s and 2000s, the pitch looked perfect. Three massive markets (defense, medicine and textiles) were openly hungry for new high-performance materials. The biology was spectacular and well-documented. And unlike most advanced materials, spider silk came with a built-in sustainability narrative: bio-based, biodegradable, produced from renewable feedstocks.

Investors who funded early spider silk companies had reason for confidence. They were applying a framework that had worked brilliantly in pharmaceutical biotech: identify a biological molecule with exceptional properties, engineer an organism to produce it at scale, then sell the resulting product into a market desperate for it. It had worked for insulin, erythropoietin and many other therapeutic proteins, and there seemed no reason it would fail for silk.

The flaw in this analogy is that therapeutic proteins are priced for the value of the treatment they deliver, in doses measured in milligrams, whereas fibers are sold by the kilogram or the tonne into markets where most materials cost a few dollars per kilogram. A kilogram of spider silk has to compete with a kilogram of Kevlar, which typically costs a few tens of dollars depending on grade. The pharmaceutical model works because a treatment is priced against what it does for a patient, not against the next-cheapest molecule. The spider silk model had to work in a commodity market where a buyer can always get performance fiber from another supplier at a fraction of the price.

This difference was systematically underweighted in early valuations. Investors modeled Total Addressable Markets in the billions, which was technically accurate for the defense, medical and textile industries combined, but did not adequately model what share of those markets spider silk could realistically capture at its actual production cost.

The Structural Incompatibility of VC and Materials

Venture capital funds are structured around a fundamental timeline: raise money from limited partners, deploy it into companies, generate returns, and distribute proceeds, typically within a ten-year fund life that is sometimes extended by a year or two. The deadline comes from the legal and financial structure of the funds themselves: limited partners such as pension funds, endowments and family offices commit money for a defined period and expect it back.

A new high-performance fiber has historically needed a decade or more to go from laboratory discovery to profitable commercial-scale production—Kevlar reached the market within about seven years of its 1965 discovery but took far longer to pay off, and others have taken one to two decades. During that time, you need to demonstrate protein production, optimize the spinning process, prove batch-to-batch consistency, pass regulatory review for target applications, complete customer validation trials, build or contract for production facilities, and finally ramp to commercial volumes. Each of these steps can take years. Several require sequential completion.

When you put a ten-year fund structure against a development timeline that can run longer, the result is predictable: companies are pushed to claim commercial readiness before they have it. A management team that tells investors they need fifteen more years will not raise the next round. A team that says ‘we’re two years from commercial launch’ will. The result is a persistent, structural optimism bias that destroys both the company and its investors’ capital.

The consequence showed up in a pattern that became recognizable across spider silk companies: launch dates slipped year after year. Spiber and Goldwin unveiled the Moon Parka prototype in 2015 for a planned 2016 release; it finally went on sale, as a 50-piece limited run, in December 2019. Timelines stretched, and new funding rounds were raised on the promise of the next milestone rather than on a reckoning with the last.

The Unit Economics

Even setting aside the timeline problem, the unit economics of spider silk have never worked. Recombinant spider silk remains expensive: published techno-economic models of complete fiber production (fermentation, purification and spinning) range from about $760 per kilogram for a first-of-a-kind plant to a few tens of dollars under optimistic assumptions, and no producer has disclosed its actual cost. A more recent model of commercial-scale E. coli-based fiber production arrived at a minimum selling price of roughly $15 to $88 per kilogram. That range is a modeled floor, and no producer has shown that it can reach it.

Compare this to the materials spider silk needs to displace. In 2025, virgin polyester staple fiber sold for roughly $0.80 to $1.20 per kilogram depending on region, and nylon 6 resin for roughly $1.30 to $2.80. Para-aramids such as Kevlar, among the most expensive established performance fibers, typically cost a few tens of dollars per kilogram, more for specialty grades. Industrial-grade carbon fiber has been estimated to cost roughly $10 to $25 per kilogram to make; aerospace grades cost far more.

Suppose spider silk protein costs fell to $20 to $30 per kilogram, the level Spiber itself identified as the threshold for widespread adoption and far below anything demonstrated at scale. That would rival Kevlar but still cost roughly seven to forty times as much as nylon or polyester. And you still need to spin it. Spinning conditions reshape every property of the fiber, and no one has yet held the right balance of strength, stretch and toughness while scaling up to industrial throughput. Slow, carefully controlled spinning adds cost, because a slow line turns out less fiber per hour.

A fiber that costs several times what Kevlar costs cannot win on price. One that costs ten times as much can only survive in niches where customers care so little about cost that they’ll absorb the premium without complaint. Those niches exist, but they are small, and they don’t justify the scale of investment poured into this sector.

Analysis — Why 'Almost Competitive' Is the Worst Place to Be

The economic dead zone in materials is when your product is too expensive for commodity markets but not differentiated enough to command luxury or medical pricing. At $100/kg, spider silk cannot replace $50/kg Kevlar, because for most purchasers its performance advantage does not justify the premium. But it also lacks the biocompatibility proof, regulatory approval, and production consistency to command the far higher prices that medical-device materials can carry. A material caught in the middle has few customers, and the investor capital spent to reach 'almost competitive' produces no return.

The Soft Exits That Never Made Headlines

Most spider silk companies didn’t fail with a dramatic bankruptcy filing or an investigative exposé. They faded. Nexia Biotechnologies, the goat-silk company that launched the industry’s first investment wave, sold its main (non-silk) Protexia business to PharmAthene in 2005, kept its BioSteel program to divest, and went bankrupt in 2009. Two of its goats ended up at the Canada Agriculture Museum in Ottawa; others were trucked from Canada to Randy Lewis’s lab at the University of Wyoming and later to Utah State University, where they continued as research subjects rather than commercial assets. Kraig Biocraft Laboratories, which built its model around transgenic silkworms, has pivoted repeatedly between military applications, medical devices, and consumer textiles, now trading as a penny stock despite opening a production center in 2024 that it says is eight times larger than its previous one, with capacity for up to 25 tonnes a year when fully utilized.

Bolt Threads developed its Microsilk spider-silk fiber (2017) and b-silk cosmetic ingredient (2019) alongside Mylo, a mycelium-based leather. When Mylo failed to reach commercial scale, Bolt discontinued it in 2023 and went public in 2024 on its silk-protein business. Within months its market value fell from roughly $230 million to under $10 million, after the company had raised, by its CEO’s account, about $334 million. AMSilk sold its cosmetics division in 2019 to concentrate on high-performance silk materials, then raised new capital across several rounds to scale production with contract manufacturers, and in 2026 reached luxury fashion racks via Balenciaga. Seevix Material Sciences, an Israeli spider silk startup, took an investment from ASICS’s venture arm in 2020, alongside a plan to develop sporting goods together, and it remains a small independent company.

Most deep-tech ventures fail, so what stands out in this pattern is the silence around the failures. In software startups, failures generate post-mortems and lessons learned. For most of the spider silk industry’s history, the exits were quiet: companies reduced their burn rates gradually, stopped issuing press releases, let their websites go stale, and eventually stopped existing without announcement. Their knowledge survived in patents and publications; their capital was gone. That changed in 2025–26, when the two best-funded players suffered very public setbacks: Spiber went through a debt restructuring and Bolt was delisted from Nasdaq.

What Works: Manufacturing Reality and the Consistency Problem

In late 2013, AMSilk began selling its recombinant spider silk protein worldwide as a cosmetics ingredient, billed as the first functional silk tested and approved for cosmetic formulations. Instead of fiber for bulletproof vests, the product was an ingredient for skin-care products: a protein that could be incorporated into skin creams to provide a silky texture and claimed skin benefits.

This pivot, which drew little attention in the materials science press, was the most commercially realistic thing the spider silk industry had done in twenty years. And it revealed the template followed by every real spider silk success since: find the application where the material’s properties matter, where volume requirements are small, where the production cost can be absorbed by the product’s price, and where the regulatory path is navigable.

The Tyranny of Consistency

Beyond the spinning bottleneck and the cost structure, spider silk faces the tyranny of consistency: the industrial requirement that every batch, not only the average one, perform identically within tight specifications, and that the producer be able to prove it.

In software, inconsistency can be patched. A software bug that affects a tiny share of users gets a hotfix that deploys to all users simultaneously. In physical materials, inconsistency is catastrophic. A batch of sutures slightly below its specified tensile strength goes into patients, and a run of body armor fiber with slightly different crystalline structure fails in the field. Neither can be fixed by a software update or recalled through an app notification.

This difference in error tolerance between physical materials and digital products explains why materials manufacturers face regulatory and quality requirements that software companies rarely encounter. ISO 13485 governs medical device manufacturing with requirements for documented process validation, risk management, and traceability to individual production lots. Ballistic-armor standards require performance testing after environmental conditioning, for example ten days of tumbling at 65°C and 80% humidity under U.S. NIJ Standard 0101.06, and military qualification adds further temperature, humidity and aging trials. Even consumer textile applications require stability testing for washing, UV exposure, and mechanical fatigue.

For a material made through a biological process, where minor variations in fermentation temperature, nutrient composition or microbial strain performance can alter protein structure, meeting these consistency requirements is difficult. The spider produces silk that is good enough for its own purposes, refined over some 380 million years of evolution, yet even natural dragline silk varies considerably between species, individuals and spinning conditions. Industry needs something the spider never had to deliver: identical performance in every batch.

The Medical Niche: Where It Works

Medical applications are among the most promising niches for spider silk, because the economics align in a way that textiles and defense do not. A medical-grade suture might use less than a gram of material. A tissue scaffold might use ten grams. A drug delivery coating on an implant might use milligrams. At these quantities, even a material costing $500 per kilogram adds only a few cents or dollars to the final product’s cost—which itself might sell for hundreds or thousands of dollars.

Beyond its Biosteel fiber, AMSilk has developed thin silk-protein coatings for medical implants. In animal studies, such coatings reduced the foreign body response—the inflammatory reaction and scar capsule the immune system forms around synthetic implants. This is where the material has an edge: a well-purified silk protein can be more compatible with biological tissue than many synthetic polymers. AMSilk worked with German implant maker Polytech on silicone breast implants with a slowly degrading spider silk coating, which entered first-in-human safety testing in 2018, and it partnered with Evonik Industries to produce proteins at industrial scale at Evonik’s Slovak fermentation facility.

Spider silk is being studied for sutures, wound dressings, tissue scaffolds, drug delivery and peripheral-nerve repair. There the material shows real promise, since its degradation products are biocompatible and non-toxic, unlike those of many synthetic polymers. It also has clear disadvantages, and in vivo evidence remains limited and clinical trials are needed.

The Compound Failure: Five Problems That Had to Be Solved Simultaneously

The obstacles that have kept spider silk from industrial scale are above all spinning, but also purification cost, contamination, batch-to-batch consistency, capital intensity, and the gap between laboratory results and industrial specifications. Grouped together, they form five problems that have to be solved at once: protein cost, industrial spinning, preserving mechanical properties at scale, consistency, and meeting industrial specifications. Each is hard on its own, and they compound, so solving one in isolation does almost nothing.

Suppose a company solves only the fermentation cost problem and can make spider silk protein at $15 per kilogram, roughly Kevlar’s price. It still cannot spin that protein into fiber without destroying the toughness that makes it valuable, and the slow, controlled spinning that preserves toughness turns cheap protein into expensive fiber. The cost advantage evaporates. Solve only the spinning problem instead, and the beautifully spun fiber is made from protein that still costs many times what Kevlar costs, so there is still no market.

Solve both, but not consistency, and one batch in a run comes out weaker because the protein folded differently in the tank. Neither defense contractors nor medical device companies will accept that. The only customers who might are luxury fashion brands, and they need proof of sustainability claims and stable supply, not just good average performance.

The compounding nature of these failures is what made spider silk resistant to the ‘find the hardest problem, solve it, and iterate’ approach that works in software. In software, partial solutions add partial value. In spider silk, partial solutions are often worth nothing commercially, because each unsolved bottleneck eliminates an entire category of potential customers.

What Could Still Change the Math

Three technologies, each real and in active development, could make the next decade different. They could reshape the economics and capabilities of spider silk production in ways that weren’t possible when the first generation of companies tried and failed.

Microfluidic Biomimetic Spinning

The fundamental problem with scaling the spider’s spinning process is that the conditions inside its silk duct are hard to reproduce at industrial scale. At the spider’s microscopic dimensions, flow, shear and chemistry are carefully staged and controllable. At industrial speeds, shear and stretching rates rise far beyond what the spider applies, and the duct’s finely staged chemistry is difficult to copy. One proposed solution leaves the duct at its natural size and builds millions of microscopic versions of it running in parallel.

Microfluidic spinning uses lab-on-a-chip technology to create channels that precisely replicate the spider’s pH gradients, ion concentrations, and shear forces at the appropriate microscale. A bio-inspired microfluidic chip has produced recombinant spider silk fiber, and microfluidic devices had earlier spun silkworm silk-fibroin fibers whose properties could be tuned by adjusting flow parameters, evidence that the approach works at small scale.

Microfluidic spinning works with the physics of small-scale flow that lets the protein align properly. The obstacle is parallelization: industrial throughput would need thousands or millions of microchannels running in step. Nothing in physics forbids that; the difficulty is building and operating so many channels at once. Related spider-inspired approaches are being commercialized: Oxford spin-out Spintex Engineering, for example, draws silk-protein fibers from a gel at room temperature, though not on microfluidic chips.

AI-Designed Silk Proteins

The second development is the application of machine learning to protein sequence design. Natural spider silk proteins evolved to work in spiders, not in fermentation tanks or industrial spinning lines at the temperatures and pressures of human manufacturing. Machine learning models offer the possibility of designing silk-like proteins optimized for human manufacturing while retaining the structural features that give silk its mechanical properties.

In 2024, researchers at MIT and Tufts University demonstrated a generative large-language model trained on major ampullate spidroin sequences and associated fiber-level mechanical properties. The model could design novel protein sequences targeting specific combinations of mechanical properties. In effect, the model is an AI that generates custom silk proteins for custom applications, so that design no longer depends on what evolution happened to produce.

A later GPT-based generative model, fine-tuned on major ampullate spidroin repeat sequences, allows design of proteins with customizable mechanical property targets. So far these designs exist mainly in silico: the new sequences have yet to be produced and spun at scale. The Baker Lab at the University of Washington has gone further and designed fibrous protein material from scratch: using Rosetta and ProteinMPNN, a machine-learning tool for protein sequence design, it created entirely new protein building blocks that assemble into precisely patterned, length-tunable nanofibers.

The practical promise of AI-designed silk proteins is that they could be engineered to express more efficiently in yeast, fold more reliably during fermentation, and assemble into fiber more readily during spinning. A protein designed from the ground up for manufacturability rather than for a spider’s survival could address several bottlenecks at once.

Cell-Free Biomanufacturing

Living cells are complicated. Bioreactors must maintain sterile conditions, control temperature and pH, manage dissolved oxygen, feed nutrients, and remove waste products—all while keeping billions of cells alive and productive. Contamination can wipe out an entire batch in hours. Yields are never perfectly consistent.

Cell-free biomanufacturing proposes to bypass living cells, using cell extracts (or, in costlier systems, purified components) in controlled reaction vessels to synthesize proteins. Without living cells to keep alive, there is no culture to be lost to contamination and fewer competing demands on the feedstock. The reaction environment can be precisely controlled.

Analysis — Why Cell-Free Silk Synthesis Is Still Hard

Cell-free protein synthesis for spider silk proteins faces a compounding series of challenges. The silk proteins themselves are among the most difficult to produce: they are enormous (some natural spidroins exceed 300 kilodaltons), highly repetitive (which confuses cellular synthesis machinery), and prone to aggregation at the very high concentrations (around 30% protein or more) that natural spinning dope reaches. In a cell-free system, achieving these concentrations without premature aggregation, while keeping the protein in the correct metastable, spinnable state, has not yet been demonstrated at any practical scale: cell-free synthesis of spidroins was first shown in outline in 2013, and the first system to produce, purify and characterize them was reported only in 2025, at laboratory scale. Additionally, the enzymes required for cell-free silk protein synthesis are themselves complex biological molecules with limited stability and high cost. Cell-free biomanufacturing works well for small proteins needed in tiny quantities. Spider silk is needed in kilograms rather than micrograms, and at that scale the economics have not yet closed.

What Would Count as a Real Breakthrough

Given the five-problem structure of the spider silk challenge, a ‘breakthrough’ shouldn’t be celebrated unless it addresses at least two bottlenecks simultaneously. Such a breakthrough might be a microfluidic spinning system that achieves 1,000 meters per hour throughput while maintaining 80% or more of native silk’s toughness across 100-kilogram production batches, or an AI-designed protein that can be produced at under $15 per kilogram in standard fermentation, requires no specialized spinning process, and achieves 70% or more of native dragline silk properties consistently.

Neither of these has been demonstrated. Both are scientifically plausible given current research trajectories. The open question is whether they will arrive in time to rescue companies that have been burning cash for decades, and whether the market will still be waiting when they do.

Spider Silk vs. the World

The spider silk story has always been told in comparison: stronger than steel, tougher than Kevlar, better than everything. These comparisons made for excellent press releases. They were also misleading in important ways, and they influenced investment decisions, research priorities, and public understanding of the technology for three decades.

An Honest Materials Comparison

Spider silk’s mechanical properties, measured on natural dragline silk from orb-weaving spiders such as the European garden spider (Araneus diadematus), are exceptional. Dragline silk has a tensile strength of approximately 1.0 to 1.5 GPa, a breaking strain of 15 to 40%, and a toughness, measured as energy absorbed per unit volume before failure, of approximately 160 MJ/m³. This toughness is higher than that of most engineered materials.

But ‘tougher than Kevlar’ requires context. Kevlar’s toughness is approximately 50 MJ/m³, lower than spider silk’s, but its tensile strength reaches 3.6 GPa, more than double silk’s. Kevlar is also far stiffer, with a Young’s modulus of roughly 70 to 140 GPa depending on grade, versus about 10 GPa for spider silk. For ballistic applications, stiffness matters: stopping a fast-moving projectile benefits from both toughness and stiffness. Carbon fiber offers extreme stiffness, roughly 230 to nearly 600 GPa for common grades, but breaks after only about 0.7 to 2.2% elongation, depending on grade. Ultra-high-molecular-weight polyethylene (UHMWPE, sold as Dyneema) achieves a tensile strength of 2.4 to 3.5 GPa with exceptional chemical resistance and low density.

Spider silk wins on toughness and elongation, and it matches high-grade steel in absolute strength—which, given its much lower density, makes it several times stronger than steel per unit weight. It loses on absolute tensile strength, stiffness and heat resistance (Kevlar does not melt and withstands brief exposures above 400°C, whereas dry spider silk keeps its properties only up to roughly 150–200°C), and it is unusually sensitive to water, which can make it shrink dramatically. On biocompatibility the early evidence favors it, though mostly from animal studies. And it loses badly on cost.

Materials purchasing decisions turn on a narrower question than which material is toughest: which one hits the required performance threshold at acceptable cost. Spider silk consistently fails this test for bulk applications because it’s too expensive, even where its properties are superior. And in applications where cost is secondary, such as medicine and defense, it faces qualification and consistency hurdles that the incumbent synthetic fibers cleared decades ago.

The Sustainability Narrative Under Scrutiny

Spider silk’s commercial positioning has increasingly emphasized sustainability: renewable feedstocks in, a biodegradable product out. These claims are partly true and partly greenwashing.

The bio-based claim is genuine but incomplete. Spiber’s Thailand facility uses sugarcane as its primary feedstock—a renewable agricultural input. The fermentation process uses microorganisms rather than petroleum-derived monomers. Spiber reports that its undyed protein yarn biodegrades in seawater within about six months under standard (ISO 23977-1) testing. These are real environmental advantages compared to Kevlar production, which uses petroleum-derived para-phenylenediamine and terephthaloyl chloride and produces significant chemical waste streams.

But bio-based production is not inherently low-impact. Industrial fermentation requires significant energy for temperature control, agitation, aeration, and sterilization. It requires large quantities of water. Agricultural feedstocks have their own land use and fertilizer implications. Purification processes for proteins often use chemical solvents and chromatography resins that generate their own waste streams. Spiber and AMSilk have published externally reviewed cradle-to-gate life-cycle assessments, but these stop at the factory gate and rest on modeled assumptions: Spiber’s favorable comparison with cashmere and wool assumes renewable power and a fully running plant. Independent academic models for E. coli-made silk fiber range from roughly 17 to over 500 kilograms of CO₂-equivalent per kilogram, depending on yields and energy assumptions.

Spiber has acknowledged this complexity, setting a target to replace at least 50 tonnes a year of the cane sugar used at its Thai plant with sugars from non-edible biomass such as bagasse by 2026, which suggests the company does not see food-crop sugar as the ideal long-term input. The company has also co-founded the BioCircular Materials Alliance to develop end-of-life protocols for protein materials.

The biodegradability claim, meanwhile, is true and, for most target applications, irrelevant. For body armor, biodegradability is a liability. For aerospace components, a fiber that shrinks and weakens when wet is unsuitable, whatever happens to it in a landfill. For medical implants intended for long-term function, degradation is a design parameter that must be controlled. Biodegradability matters for casual textiles, whose landfill waste is a real environmental problem, but those applications are exactly where the cost premium is least tolerable.

The Myth of Universal Material Supremacy

Perhaps the most damaging misconception in the spider silk narrative is the implicit claim of universal superiority: that spider silk is better than the alternatives and would naturally dominate once production scaled.

No material is universally best. Every engineering application has a specific, quantitative set of requirements (strength, stiffness, toughness, thermal range, chemical resistance, weight, cost per unit), and materials are selected based on how well they satisfy that specific requirement set, weighted by the priorities of the application. Spider silk is optimal for essentially none of these requirement sets when cost is included in the evaluation.

The market didn’t wait for spider silk, and its competitors kept improving. Dyneema now offers specific strength that rivals or exceeds spider silk at a fraction of the cost. Carbon fiber composites have become sophisticated enough to offer impact resistance through design features that compensate for brittleness. Kevlar has evolved through multiple generations. By the time spider silk could potentially compete on cost, the incumbent materials will have another decade of optimization behind them.

The Survivors and Their Niches: Who’s Still in the Race

By the mid-2020s, the spider silk industry looked nothing like what its founders imagined in 1995. The companies still operating had found narrow, defensible niches where the material’s unique properties justify its current costs, and had built their strategies around those niches rather than around replacing Kevlar or other mass-market ambitions. Even so, survival has not been guaranteed: in 2025–26 the two best-funded players, Spiber and Bolt Threads, both hit very public financial walls.

The Leaders and Their Pivots

Spiber was the largest and most-funded player. Having raised more than ¥100 billion in equity and debt, it opened its first commercial-scale production facility in Thailand’s Rayong Province (inaugurated in 2021, operating from 2022), with capacity for several hundred tonnes of protein a year. A second plant in Clinton, Iowa, built with agricultural giant ADM and financed with roughly ¥40 billion of debt raised by securitizing the business, ran over budget, and when ¥35 billion of that debt fell due at the end of 2025, Spiber could not repay it. In 2026 it went through an out-of-court restructuring: from April 1, 2026, the business, minus the US operation, was moved into a new company led by Maya Kawana, while the old entity is being wound down. In October 2026 the new Spiber also began offering its fermentation scale-up capability to other companies as a contract service (SPIBER BIOFOUNDRY). The company explicitly positions its product as ‘Brewed Protein’ rather than as spider silk per se, and has pivoted from trying to replicate spider silk’s specific properties to designing proteins optimized for human applications.

In a 2024 sponsored feature, Spiber said its Thai plant had produced about 100 tonnes of recombinant protein the previous year; by 2025, some 45 brands had used Brewed Protein fibers in 193 products. The product has reached ordinary retail, in luxury parkas, scarves and knitwear sold at premium price points. No previous spider silk company had achieved commercial traction at this scale.

AMSilk, based in Neuried near Munich, makes its silk proteins through contract manufacturers, chiefly Evonik in Slovakia, and has agreed further dedicated capacity with Ajinomoto Foods Europe in France. Under a 2026–2028 investment plan backed by a European Investment Bank loan, it is also adding downstream fiber spinning, yarn production and chemical recycling at a contract manufacturer’s site in Lovosice, Czech Republic. It has concentrated on high-value textile, automotive and consumer applications, with medical coatings as a smaller line. In the process it has built what may be the most durable business model in the sector: selling a specialty protein to manufacturers, rather than trying to manufacture finished goods itself. Its showcase projects have included an Omega watch strap (2019), door pulls in Mercedes-Benz’s VISION EQXX concept car (2022) and Adidas’s Futurecraft Biofabric prototype shoe (2016); its yarns reached luxury retail in Balenciaga’s Spring 2026 collection.

Kraig Biocraft Laboratories, the transgenic silkworm company, has taken a different path: using domesticated silkworms’ existing spinning apparatus to produce a hybrid silkworm–spider silk fiber through the worm’s native silk-production machinery, sidestepping the hardest part of industrial spinning. In September 2024, the company opened a production center in Vietnam that it says is eight times larger than its predecessor, able to support up to 25 tonnes a year when fully utilized. A 2016 U.S. Army contract worth up to about $1 million funded tests of its fiber for ballistic fabrics, and in 2025 it announced U.S. trademark registrations for its SpydaSilk consumer brand. In September 2026 it reported shipping its first, deliberately small, commercial yarn order to an unnamed performance-sports brand.

Seevix Material Sciences of Israel received a strategic investment from ASICS Ventures in 2020, giving a major consumer brand a strategic stake in spider silk technology. Spintex Engineering, a University of Oxford spin-out, is developing a low-energy, spider-inspired process that draws silk-protein fibers from a gel at room temperature, supported by EU and Oxford seed funding. Inspidere in the Netherlands, a biobased-materials studio, has explored spider silk among other materials, including for wound care.

Where Government Funding Fits In

Venture funding for spider silk companies, by one count, peaked in 2021 and fell in 2022 amid the wider market downturn, though a few firms, notably AMSilk, have continued to raise sizeable rounds. Public research grants remain an important source of support for the underlying science. The National Science Foundation’s FY2025 budget request proposed about $155 million for biotechnology through its Biological Sciences directorate, and the Department of Energy requested $945 million for Biological and Environmental Research, of which Congress enacted $870 million. Only a small part of such programs supports structural-protein research, and subsequent budget requests for FY2026 and FY2027 proposed deep cuts to both.

Government research funding works on different terms than venture capital: DARPA programs typically run three to five years, and NSF and DOE grants are renewed competitively, but a research line that keeps winning grants can be sustained for a decade or more without having to show a commercial return. Military interest in ultra-high-performance materials for ballistic protection and lightweight structural components provides a patient, mission-oriented customer for spider silk research. This patient capital is helping to keep the technology alive while private markets wait for clearer signals of commercial viability.

The contrast between the two kinds of money shows that materials development operates on timelines that markets can’t efficiently fund. It also suggests that commercial breakthroughs, if they come, will arrive by a different path than originally envisioned: through sustained research partnerships between government, academia and specialized companies building toward specific, defensible applications, rather than through VC-backed startups racing to a textile IPO.

Thirty Years of Five Years Away

The record of missed forecasts is long. In 1991, Stephen Lombardi, a molecular biologist at the U.S. Army’s Natick research center, said that commercializing synthetic spider silk was “about five years away.” Nexia Biotechnologies, which raised tens of millions of dollars and went public in 2000 on the promise of “BioSteel” from goat milk, was bankrupt by 2009 without having sold fiber at scale. Spiber’s Moon Parka, promised for 2016, reached customers more than three years late. Bolt Threads called its 2017 spider-silk necktie a first step toward wider products, then put its fiber ambitions aside for mycelium leather and cosmetics.

None of these forecasts came from fools or frauds; they came from informed people working with real technology, and none proved correct. Their record is a measure of how hard materials development is to forecast, and a warning for the next generation of deep-tech materials.

Two Futures

The conservative scenario (call it the baseline) is that spider silk continues on its current trajectory: a restructured Spiber scales Brewed Protein output at its Thai plant toward its several-hundred-tonne capacity, serving luxury textile and specialty material markets at premium price points. AMSilk builds a sustainable business in high-value textiles, with medical coatings and industrial specialties alongside. Kraig Biocraft supplies small quantities to military research programs and premium consumer textiles. The total market reaches roughly $610 million by 2035, as one market-research firm projects. That is large by startup standards but a niche market by materials industry standards.

In this scenario, spider silk never becomes a commodity material. It finds lasting, commercially sustainable niches in medical applications and premium products. Its technical limitations (spinning quality, cost, heat and water sensitivity, consistency at scale) prevent it from displacing Kevlar, nylon, or carbon fiber in bulk applications. That would be real commercial success compared with the failures of the 1990s, and an underwhelming result next to the original vision.

The optimistic scenario requires the two breakthroughs described above to arrive together: a controlled spinning process that reaches industrial throughput without losing most of the toughness, and a fermentation-plus-purification cost that falls to Kevlar’s level at commercial scale. If both occur, spider silk fiber could become cost-competitive with Kevlar within the 2030–2040 window and begin to penetrate defense, aerospace, and high-performance textile markets.

Lessons for Deep-Tech Investors: The Three Structural Traps

Spider silk’s thirty-year history offers a case study in three structural dynamics that make materials science investments hostile to venture capital returns.

The capex gravity trap: every step toward commercial scale requires massive capital investment—bioreactors, purification equipment, spinning systems, quality control labs, pilot plants, commercial facilities. This capital must be deployed before revenue is generated and cannot be recovered if the business fails. Fermenters can find other users; a spinning line and a purification train tuned to one protein have few, and when the company fails they are worth a fraction of their cost to anyone else.

The validation drag trap: materials require years of customer validation before significant purchases. A defense contractor cannot commit to buying thousands of tonnes of spider silk armor fabric until it has completed performance testing across extreme conditions, aging studies, and supply chain reliability assessments—a process that typically takes three to five years or more. During those years, the spider silk company must sustain operations without revenue, burning through investor capital on the hope that validation will eventually result in a purchase.

The integration trap: industrial customers have supply chains, manufacturing processes, and quality systems optimized around existing materials. Switching to a new material requires not just buying different fiber but renegotiating supplier contracts, retraining operators, retesting and recertifying products, and absorbing the risk that the new material behaves differently in edge cases. These switching costs are substantial, often exceeding the material cost premium that the new material represents, and they create inertia in industrial procurement. You often need to be dramatically better or cheaper just to get a customer to switch, and spider silk hit all three traps at once.

What Success Would Look Like

One reasonable benchmark for industrial success, our own rather than an industry standard, would require four simultaneous achievements. Production volume would need to reach about 1,000 tonnes per year to matter to an industrial buyer beyond luxury goods. Cost of goods sold, including fermentation, purification and spinning, would need to reach $30 per kilogram or below to compete with Kevlar; medical uses tolerate far more, as the coating business shows. Mechanical properties of the final fiber would need to achieve at least 80% of natural dragline silk toughness consistently across batches. And a major industrial customer, such as a defense contractor, an automotive manufacturer or a major apparel brand operating at scale, would need to commit to purchase at those volumes and prices.

None of these four conditions currently exist simultaneously. Spiber’s Thailand plant was built for several hundred tonnes of protein a year and reportedly produced about 100 tonnes in 2023, but fiber spinning from that protein still faces quality and cost challenges. The medical coating applications don’t require the fiber properties—they use the protein in different formats. Meeting all four at once is the target that justifies further investment and research, and it has stayed out of reach for three decades.

As a rough forecast, a niche-viability scenario is achievable within the 2025–2030 window if the restructured Spiber and its peers hold their current course. A scenario in which spider silk becomes competitive as a commodity requires the convergence of AI protein design breakthroughs, scalable microfluidic spinning, and continued cost reduction in fermentation. Under optimistic assumptions about research trajectories, this convergence could occur in the 2035–2045 window. Under historical assumptions about materials development timelines, it could easily be 2050 or later.

The Final Verdict: What the Miracle Fiber Teaches Us

Today, spider-silk-inspired materials exist. You can buy products containing them—Spiber-based knitwear and outerwear from luxury and outdoor brands, and, since 2026, Balenciaga garments made with AMSilk yarn; in September 2026, Kraig Biocraft shipped its first small commercial order of spider silk yarn. Spider silk has not failed, but its success is nowhere near proportional to the investment and attention it has received.

The spider’s engineering is extraordinary: a hierarchical protein composite refined over roughly 380 million years to perform functions no human-engineered material matches across all dimensions simultaneously. Its properties and applications were real, and the medical promise still is.

What was wrong, as the industry learned slowly and at great expense, was the assumption that understanding nature’s solution implies the ability to replicate it in a factory. The spider’s spinneret is a biological system embedded in an organism, inseparable from the organism’s physiology and evolved for entirely different optimization criteria than industrial manufacturing. A factory copy of the spinneret has so far failed to match it at useful throughput for that reason, even though the biology behind it is sound.

The industry is left with a set of useful materials, carved from much more modest ambitions than their founders announced, finding real value in niches where their specific properties matter: medical coatings that may one day reduce implant complications, luxury textiles that offer biodegradability at premium price points, and military research programs pursuing next-generation performance materials with patience that private markets couldn’t sustain. The research behind them has also advanced the understanding of protein engineering, soft matter physics and biomaterial design, and that knowledge will influence materials science for decades whether or not spider silk itself ever reaches commodity relevance.

Between the proof that something can work and the demonstration that it can work profitably, at scale, consistently and in competition with established alternatives lies a gap, and spider silk has spent thirty years in it. The spider, meanwhile, spins the stuff before breakfast.

Related articles

• The rare earth supply chain: the hidden dependency behind every modern device
• The Great Stagnation: why productivity growth slowed and whether it can recover
• The European Green Deal was never just about the climate

Further reading

As an Amazon Associate, Eikleaf earns from qualifying purchases. The book links below are affiliate links: if you buy through them, we may earn a small commission at no extra cost to you.

Recommended videos

Gen AI Disclaimer

Some contents of this page were generated and/or edited with the help of a Generative AI.

Media

Skyler Ewing – Pexels

Pixabay – Pexels

Layton Photos – Pexels

Key Sources and References

Bolt Projects Holdings (Bolt Threads). SEC filings: Form 424B3 proxy statement/prospectus (July 2024); Form 8-K, 19 Aug 2024 (closing); Form 8-K, 7 Nov 2024 (Nasdaq bid-price notice); Form 10-K FY2024; Form 8-K, January 2026 (Nasdaq delisting; suspension 5 Jan 2026). Nasdaq trading began 14 August 2024; deal announced October 2023 at $346.1M pro forma enterprise value. https://www.sec.gov/Archives/edgar/data/1841125/000121390024062617/ea0202730-11.htm · https://www.sec.gov/Archives/edgar/data/1841125/000121390024070809/ea0211631-8k_bolt.htm · https://www.sec.gov/Archives/edgar/data/1841125/000121390024095488/ea0220322-8k_bolt.htm · https://www.sec.gov/Archives/edgar/data/1841125/000184112525000017/bslk-20241231.htm · https://www.sec.gov/Archives/edgar/data/1841125/000184112526000003/bslk-20251231.htm

BSLK daily price data, August–September 2024. Yahoo Finance. (First-day close used for the ~$230M market capitalization.) https://query1.finance.yahoo.com/v8/finance/chart/BSLK?period1=1723593600&period2=1726200000&interval=1d

Bolt Threads to go public with 346 million dollar deal. FashionUnited, October 2023. https://fashionunited.uk/news/business/bolt-threads-to-go-public-with-346-million-dollar-deal/2023100671983

Conocé Bolt Threads, la empresa que va a debutar en Wall Street. Forbes Argentina (Forbes repost), October 2023. (About $334M raised, per CEO Dan Widmaier.) https://www.forbesargentina.com/negocios/conoce-bolt-threads-empresa-va-debutar-wall-street-y-tienen-ver-telas-arana-eso-n41844

Bolt Threads debuts its first product, a $314 tie. TechCrunch, March 2017; Synthetic spider silk for sale in a $314 necktie. MIT Technology Review, March 2017. https://techcrunch.com/2017/03/10/bolt-threads-debuts-its-first-product-a-314-tie-made-from-spiderwebs/?ncid=rss · https://www.technologyreview.com/2017/03/10/153305/synthetic-spider-silk-for-sale-in-a-314-necktie/amp/

【解説】私的整理のスパイバー (Spiber’s private restructuring explained). WWDJAPAN, March 2026. (Funding over ¥100bn incl. debt; FY2024 revenue ¥414M.) https://www.wwdjapan.com/articles/2364123

スパイバー破綻が示すディープテックの難路 (What Spiber’s collapse says about deep tech). Nikkei, 28 March 2026. https://www.nikkei.com/article/DGXZQOUC268N40W6A320C2000000/

Spiber business transfer and liquidation plan. Tokyo Shoko Research, 26 March 2026. (FY2025 revenue ¥177M; ¥35bn loan due 28 Dec 2025.) https://www.tsr-net.co.jp/data/detail/1202684_1527.html

Spiber restructuring. FashionSnap, 1 April 2026. https://www.fashionsnap.com/article/2026-04-01/spiber-restructure/

Spiber Inc. New Spiber launch (1 April 2026); SPIBER BIOFOUNDRY launch (2 October 2026); Spiber and ADM to scale regenerative agriculture for Brewed Protein polymer production (2022). https://spiber.inc/en/news/new-spiber · https://spiber.inc/en/news/SPIBER-BIOFOUNDRY-Spiber-BioJapan2026-BrewedProtein · https://spiber.inc/en/news/spiber-and-adm-to-scale-regenerative-agriculture-for-brewed-protein-polymer-production

Synthetic Protein Material Company Spiber Set for Global Expansion. WIPO IP Advantage, 2022. https://www.wipo.int/web/ip-advantage/w/stories/synthetic-protein-material-company-spiber-set-for-global-expansion

Spiber Inc. Brewed Protein (seawater biodegradation, ISO 23977-1); Sustainability; LCA Summary (cradle-to-gate), July 2023; Sustainability Progress Report 2025 (non-edible biomass sugar target); BioCircular Materials Alliance progress report. https://spiber.inc/en/protein · https://spiber.inc/en/sustainability · https://spiber.inc/wp-content/uploads/2023/09/Spiber_LCA_Summary_En_20230922.pdf · https://spiber.inc/wp-content/uploads/2025/09/En_spiber_sustainability_progress_report_2025.pdf · https://spiber.inc/en/news/biocircular-materials-alliance-welcomes-new-partners-and-publishes-progress-report

Synthetic spider silk biotech firm Spiber joins Bonsucro. Bonsucro, 2020. https://bonsucro.com/synthetic-spider-silk-biotech-firm-spiber-joins-bonsucro/

Creating novel fibres from synthetic spider silk. Nature Research Custom Media (advertisement feature), 2024. (Spiber: ~100 tonnes produced in 2023.) https://www.nature.com/articles/d42473-024-00101-7

Along Came Spiber: How Synthetic Proteins Are Weaving a New Era in Materials. SynBioBeta. (Spiber: $20–30/kg identified as adoption threshold; long-term goal ~$10/kg.) https://www.synbiobeta.com/read/along-came-spiber-how-synthetic-proteins-are-weaving-a-new-era-in-materials

Artificial spider silk, imitating ‘the toughest material on earth’. Renewable Carbon News. https://renewable-carbon.eu/news/?p=49233

When fashion meets protein fibres. FashionUnited, August 2025. (45 brands, 193 products.) https://fashionunited.uk/news/fashion/when-fashion-meets-protein-fibres-biotechnology-can-be-a-powerful-force-for-good/2025080683138

Moon Parka release. Gizmodo Japan, August 2019. https://www.gizmodo.jp/2019/08/moon-parka-the-north-face.html

AMSilk GmbH. Givaudan to acquire cosmetics business of AMSilk (2019); AMSilk secures EUR 52M strategic financing (9 September 2025; €30M equity + €22M convertible bonds); AMSilk partners with Mercedes-Benz (2022); Ultrafine cradle-to-gate LCA Essentials 2024. https://www.amsilk.com/givaudan-to-acquire-cosmetics-business-of-amsilk/ · https://www.amsilk.com/amsilk-secures-eur-52m-strategic-financing-to-accelerate-commercial-growth/ · https://www.amsilk.com/amsilk-partners-with-mercedes-benz-to-present-a-sustainable-bio-based-product/ · https://www.amsilk.com/app/uploads/AMSilk-Ultrafine_Cradle-to-gate-LCA_Essentials-2024.pdf

Novo Holdings leads EUR 29m investment in bio-based silk supplier AMSilk. Novo Holdings, 2021; AMSilk raises EUR25m to scale biosilk growth. Just Style, 2023. https://novoholdings.dk/news/novo-holdings-leads-eur-29m-investment-in-bio-based-silk-supplier-amsilk · https://www.just-style.com/news/amsilk-raises-eur25m-to-scale-biosilk-growth/

Givaudan acquires AMSilk’s cosmetics business. Happi, June 2019. https://www.happi.com/issues/2019-06-03/view_breaking-news/givaudan-acquires-amsilks-cosmetics-business/

AMSilk Obtains Funding. Textile World, December 2025. (Re-report of the September 2025 €52M round.) https://www.textileworld.com/textile-world/fiber-world/2025/12/amsilk-obtains-funding/

AMSilk signs deal to scale silk production. Ecotextile News, February 2023; Evonik and AMSilk extend partnership for sustainable biotech silk materials. Renewable Carbon News, September 2025. https://www.ecotextile.com/2023021545925/news/materials-production-news/amsilk-signs-deal-to-scale-silk-production/ · https://renewable-carbon.eu/news/evonik-and-amsilk-extend-partnership-for-sustainable-biotech-silk-materials/

AMSilk project: scaling sustainable spider silk materials. EU Transition Pathways (Textiles); TECHEU VD AMSilk Advanced Materials, project 20240895 (EIB loan €30M signed 30 December 2025; spinning, yarning and chemical recycling line at a contract manufacturing organisation in Lovosice, Czech Republic). European Investment Bank. https://transition-pathways.europa.eu/textiles/projects/amsilk-project-scaling-sustainable-spider-silk-materials · https://www.eib.org/en/projects/all/20240895

AMSilk locks in dedicated production line with Ajinomoto Foods Europe. Vegconomist, 2026; Bioengineered silk enters luxury retail: Balenciaga launches AMSilk-based garments. Vegconomist, January 2026. https://vegconomist.com/manufacturing-technology/amsilk-locks-in-dedicated-production-line-ajinomoto-foods-europe/ · https://vegconomist.com/materials/bioengineered-silk-enters-luxury-retail-balenciaga-launches-amsilk-based-garments/

AMSilk holt Christian Wichert als CEO für die Kommerzialisierungsphase. FashionUnited DE, June 2026. https://fashionunited.de/nachrichten/personen/amsilk-holt-christian-wichert-als-ceo-fur-die-kommerzialisierungsphase/2026061967300/

AMSilk starts worldwide distribution of Spidersilk as cosmetic ingredient. Renewable Carbon News, November 2013. https://renewable-carbon.eu/news/?p=18091

AMSilk spider silk watch strap. Labiotech, 2019; adidas unveils world’s first performance shoe made from Biosteel fiber. adidas, 2016. https://www.labiotech.eu/more-news/amsilk-spider-silk-watch-strap/ · https://www.adidas-group.com/en/media/press-releases/adidas-unveils-worlds-first-performance-shoe-made-from-biosteelr-fiber

Breast implants with biotech spider silk. Bioökonomie.de; Zeplin et al. Advanced Functional Materials. 2014 (University of Bayreuth record). https://biooekonomie.de/en/node/101734 · https://eref.uni-bayreuth.de/7597

Kraig Biocraft Laboratories. Completes new production center, expands capacity more than eightfold (BioSpace, September 2024); Launches spider silk production (StockTitan, 23 September 2024); Over 1.3 metric tons of cocoons in a single month (BioSpace, April 2026); Four registered trademarks for SpydaSilk (GlobeNewswire, 1 April 2025). https://www.biospace.com/press-releases/kraig-biocraft-laboratories-completes-new-production-center-expands-capacity-more-than-eightfold · https://www.stocktitan.net/news/KBLB/kraig-biocraft-laboratories-launches-spider-silk-production-at-rwpplw2ztgp9.html · https://www.biospace.com/press-releases/kraig-biocraft-laboratories-shatters-production-record-delivering-over-1-3-metric-tons-of-spider-silk-cocoons-in-a-single-month-a-5x-increase-over-previous-high · https://www.globenewswire.com/news-release/2025/04/01/3053176/0/en/Kraig-Biocraft-Laboratories-Secures-Four-Registered-Trademarks-for-SpydaSilk-Brand-to-Advance-Commercialization-Strategy-for-Recombinant-Spider-Silk.html

Kraig Biocraft Laboratories announces contract with US Army. Soldier Systems Daily, July 2016. https://soldiersystems.net/2016/07/12/kraig-biocraft-laboratories-announces-contract-with-us-army-to-deliver-dragon-silk/

Kraig Biocraft Laboratories ships first commercial spider silk yarn order for performance sports brand. Pulse 2.0, 29 September 2026; KBLB quote. Stock Analysis. https://pulse2.com/kraig-biocraft-laboratories-ships-first-commercial-spider-silk-yarn-order-for-performance-sports-brand/ · https://stockanalysis.com/quote/otc/KBLB/

ASICS Ventures invests in Seevix Material Sciences, an Israeli synthetic spider silk startup. Textile World, 14 May 2020. https://www.textileworld.com/textile-world/fiber-world/2020/05/asics-ventures-invests-in-seevix-material-sciences-an-israeli-synthetic-spidersilk-startup/

Spintex Engineering (company site); Spider-inspired silk company Spintex awarded Ray of Hope Prize. Ray C. Anderson Foundation; Inspidere — About. https://www.spintex.co.uk/ · https://www.raycandersonfoundation.org/articles/spider-inspired-silk-company-spintex-awarded-ray-of-hope-prize · https://www.inspidere.com/about

A web of possibilities: Utah researcher uses goats to make one of the strongest known substances. Deseret News, 5 July 2011. https://www.deseret.com/2011/7/5/20374017/a-web-of-possibilities-utah-researcher-uses-goats-to-make-one-of-the-strongest-known-substances

The Silky, Milky, Totally Strange Saga of the Spider Goat. Modern Farmer, 2013; Spider goats display. Canadian Biotechnology Action Network. https://modernfarmer.com/2013/09/saga-spidergoat/ · https://cban.ca/?p=439

Nexia Biotechnologies announces agreement to sell all assets associated with Protexia to PharmAthene. BioSpace, 2005. https://www.biospace.com/b-nexia-biotechnologies-inc-b-announces-agreement-to-sell-all-assets-associated-with-protexia-r-to-b-pharmathene-inc-b

High Wire Artists. National Wildlife (National Wildlife Federation), February 1991. https://www.nwf.org/Magazines/National-Wildlife/1991/High-Wire-Artists

Gosline JM, Guerette PA, Ortlepp CS, Savage KN. The mechanical design of spider silks: from fibroin sequence to mechanical function. J Exp Biol. 1999;202:3295–3303. doi:10.1242/jeb.202.23.3295. https://journals.biologists.com/jeb/article/202/23/3295/8324/The-mechanical-design-of-spider-silks-from-fibroin

Agnarsson I, et al. Bioprospecting finds the toughest biological material. PLoS ONE. 2010. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011234

Ayoub NA, et al. Blueprint for a high-performance biomaterial: full-length spider dragline silk genes. PLoS ONE. 2007. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000514

Vollrath F, Madsen B, Shao Z. The effect of spinning conditions on the mechanics of a spider’s dragline silk. Proc R Soc B. 2001. https://pmc.ncbi.nlm.nih.gov/articles/PMC1088885/

Selden PA, Shear WA, Sutton MD. Fossil evidence for the origin of spider spinnerets, and a proposed arachnid order. PNAS. 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2634869/

Yang Y, et al. Toughness of spider silk at high and low temperatures. Advanced Materials. 2005. doi:10.1002/adma.200400344. https://doi.org/10.1002/adma.200400344

What is Kevlar? Arclin; Carbon fiber products. Toray Composite Materials America; Dyneema. Avient; Aramid fiber: the basics. CompositesWorld. https://www.arclin.com/kevlar/what-is-kevlar/ · https://www.toraycma.com/products/carbon-fiber/ · https://www.dyneema.com/ · https://compositesworld.com/articles/aramid-fiber-the-basics

Branković M, Zivic F, Grujovic N, Stojadinovic I, Milenkovic S, Kotorcevic N. Review of Spider Silk Applications in Biomedical and Tissue Engineering. Biomimetics (Basel). 2024;9(3):169. doi:10.3390/biomimetics9030169. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10967872/

Guessous G, Blake L, et al. Disentangling the Web: An Interdisciplinary Review on the Potential and Feasibility of Spider Silk Bioproduction. ACS Biomaterials Science & Engineering. 2024;10(9):5412–5438. doi:10.1021/acsbiomaterials.4c00145. (Cost estimates for recombinant silk; funding trends; toughness comparisons.) https://pmc.ncbi.nlm.nih.gov/articles/PMC11388149

Lu W, Kaplan DL, Buehler MJ. Generative Modeling, Design, and Analysis of Spider Silk Protein Sequences for Enhanced Mechanical Properties. Advanced Functional Materials. 2024;34(11):2311324. doi:10.1002/adfm.202311324. Preprint: arXiv:2309.10170. https://arxiv.org/abs/2309.10170

Dubey et al. Customizing Spider Silk: Generative Models with Mechanical Property Conditioning for Protein Engineering. arXiv:2504.08437, April 2025. https://arxiv.org/abs/2504.08437

Bethel NP, et al. Precisely patterned nanofibres made from extendable protein multiplexes. Nat Chem. 2023;15:1664–1671. doi:10.1038/s41557-023-01314-x. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695826/

Whittall DR, Baker KV, Breitling R, Takano E. Host Systems for the Production of Recombinant Spider Silk. Trends Biotechnol. 2021;39(6):560–573. doi:10.1016/j.tibtech.2020.09.007. https://doi.org/10.1016/j.tibtech.2020.09.007

Kinahan ME, et al. Tunable silk: using microfluidics to fabricate silk fibers with controllable properties. Biomacromolecules. 2011;12:1504–1511. doi:10.1021/bm1014624. (Silkworm fibroin.) https://pmc.ncbi.nlm.nih.gov/articles/PMC3305786

Peng Q, Zhang Y, Lu L, et al. Recombinant spider silk from aqueous solutions via a bio-inspired microfluidic chip. Sci Rep. 2016;6:36473. doi:10.1038/srep36473. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098227/

Carlson ED, et al. Cell-free protein synthesis: applications come of age. Biotechnol Adv. 2012; Hong SH, Ye X, Jewett MC. Recombinant spider silk protein production in Escherichia coli cell-free protein synthesis. AIChE Annual Meeting, 2013 (abstract 715d); Huang et al. Developing an E. coli-based cell-free protein synthesis system for artificial spidroin production and characterization. ACS Synth Biol. 2025. doi:10.1021/acssynbio.5c00241. https://pmc.ncbi.nlm.nih.gov/articles/PMC4038126 · https://proceedings.aiche.org/conferences/aiche-annual-meeting/2013/proceeding/paper/715d-recombinant-spider-silk-protein-production-escherichia-coli-cell-free-protein-synthesis-1 · https://pmc.ncbi.nlm.nih.gov/articles/PMC12090345/

Edlund AM, Jones J, Lewis R, Quinn JC. Economic feasibility and environmental impact of synthetic spider silk production from Escherichia coli. New Biotechnology. 2018;42:12–18. doi:10.1016/j.nbt.2017.12.006. https://digitalcommons.usu.edu/biology_facpub/1604

Tajipour et al. Lifecycle cost, environmental, and machine-learning value assessment for synthetic spider silk production from E. coli. Green Chemistry. 2026;28(4):1960–1971 (online Dec 2025). doi:10.1039/D5GC05082K. (Minimum selling price $14.96–$87.80/kg.) https://pubs.rsc.org/en/Content/ArticleLanding/2026/GC/D5GC05082K

Polyester staple fibre price trends. Expert Market Research, 2025; Nylon prices. Intratec; PA6 (Nylon 6) pricing report. IMARC, 2025. https://www.expertmarketresearch.com/price-forecast/polyester-staple-fibre-price-trends · https://www.intratec.us/solutions/primary-commodity-prices/commodity/nylon-prices · https://imarcgroup.com/pa6-nylon-6-pricing-report

Cook JJ, Booth S. Carbon Fiber Manufacturing Facility Siting and Policy Considerations: International Comparison. NREL/TP-6A20-66875, Clean Energy Manufacturing Analysis Center, June 2017. (Industrial-grade carbon fiber manufacturing cost $10–25/kg.) https://docs.nlr.gov/docs/fy17osti/66875.pdf

What is Venture Capital? National Venture Capital Association; Stephanie L. Kwolek. Science History Institute; Stephanie Kwolek, chemist who created Kevlar, dies at 90. WGBH/AP, 2014. https://nvca.org/about-us/what-is-vc/ · https://www.sciencehistory.org/education/scientific-biographies/stephanie-l-kwolek/ · https://www.wgbh.org/news/2014-06-20/stephanie-kwolek-chemist-who-created-kevlar-dies-at-90

Recombinant DNA insulin. NSF; Epogen, BLA 103234. Drugs@FDA. https://nsf.gov/impacts/rdna-insulin · https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103234

ISO 13485:2016 Medical devices — Quality management systems. ASEAN Trade Repository; Testing bulletproof vests. TNO; NISTIR 7627. NIST. https://atr.asean.org/standards/detail/336/iso-134852016-medical-devices-quality-management-systems-requirements-for-regulatory-purposes · https://www.tno.nl/media/7000/testingbulletproofvests.pdf · https://nvlpubs.nist.gov/nistpubs/Legacy/IR/nistir7627.pdf

National Science Foundation. FY2025 Budget Request: Biotechnology; FY2026 Budget Request: Biological Sciences. https://nsf-gov-resources.nsf.gov/files/23_fy2025.pdf · https://nsf-gov-resources.nsf.gov/files/33-fy2026.pdf

DOE Office of Science. Biological and Environmental Research FY2025 Budget Request; BER FY2027 Request Narrative. https://science.osti.gov/-/media/budget/pdf/sc-budget-request-to-congress/2025/Biological-and-Environmental-Research-3_15_24—Final.pdf · https://science.osti.gov/-/media/budget/pdf/sc-budget-request-to-congress/2027/FY-2027-Request-Narrative—BER.pdf

Defense Advanced Research Projects Agency: Overview and Issues for Congress (R45088). Congressional Research Service. https://www.congress.gov/crs_external_products/R/PDF/R45088/R45088.12.pdf

Spider Silk Market Size, Share & Growth Forecast 2035. Transparency Market Research, November 2025. (Market $160.1M in 2024; projected $610.3M by 2035.) https://www.transparencymarketresearch.com/spider-silk-market.html